No Data
No Data
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $16
Express News | Neurogene : Increases Nomination Threshold at Which Bba Has Certain Rights to Nominate One Person as Director to 14.9% of Voting Stock
Express News | Neurogene Inc - Amends Agreement With Baker Bros to Increase Nomination Threshold - SEC Filing
Neurogene Price Target Cut to $16.00/Share From $45.00 by BMO Capital
Neurogene Is Maintained at Outperform by BMO Capital
Express News | Neurogene Inc : BMO Cuts Target Price to $16 From $45